Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NICE OK For Bayer’s Eylea In AMD May Spell U.K. Trouble For Lucentis

This article was originally published in The Pink Sheet Daily

Executive Summary

NICE has given the thumbs-up to Bayer’s Eylea in wet AMD, but its impressive cost-effectiveness could spell trouble for Novartis’ Lucentis in the long run.

You may also be interested in...



NICE Rejects Avastin For Ovarian Cancer On Cost, Okays Lucentis

NICE has knocked back Avastin for ovarian cancer due to high cost, but Roche may have a plausible market strategy in place for the drug in the UK.

NICE Nod To Lucentis For ME Raises Unlicensed Comparator Issue

The U.K.’s cost watchdog NICE has waved through Novartis’ Lucentis for macular edema after the Swiss manufacturer offered a discount.

Valeant Adds Eyetech’s Macugen To Ophthalmic Portfolio

The acquisitive Canadian specialty pharma’s latest deal is a relatively small one, giving it a wet AMD treatment that lags behind Lucentis and other newcomers.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS075773

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel